Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review

BJU International

Volumn 107, Issue 7, 2011, Pages 1104-1109

  Laydner, Humberto K ^a,c   Oliveira, Paulo ^a   Oliveira, Carlos Roberto A ^a   Makarawo, Tafadzwa P ^b   Andrade, Weslley S ^a   Tannus, Matheus ^a   Arájo, José Luciano R ^a  

^a Hospital Geral Roberto Santos   (Brazil)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c Rua Dos Radialistas 181 Ap 501   (Brazil)

Author keywords

benign prostatic hyperplasia; lower urinary tract symptoms; phosphodiesterase 5 inhibitors; prostate; randomized controlled trials

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; VARDENAFIL;

ARTICLE; COCHRANE LIBRARY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MALE; MEDLINE; MICTURITION; PENIS ERECTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME;

AGED; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATIC HYPERPLASIA; PROSTATISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79953230881     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09698.x     Document Type: Article

References (39)

1. Barry MJ, Fowler FJ Jr, O'Leary MP, et al,. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 1549-57
2. Berry SJ, Coffey DS, Walsh C, Ewing LL,. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9 (Pubitemid 14026148)
3. Wei JT, Calhoun E, Jacobsen SJ,. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005; 173: 1256-61 (Pubitemid 40380548)
4. Hollingsworth JM, Wei JT,. Economic impact of surgical intervention in the treatment of benign prostatic hyperplasia. Rev Urol 2006; 8 (Suppl 3): S9-S15
5. McConnell JD, Bruskewitz R, Walsh P, et al,. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 557-63 (Pubitemid 28114643)
6. McConnell JD, Roehrborn CG, Bautista OM, et al,. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. N Engl J Med 2003; 349: 2387-98 (Pubitemid 37542987)
7. RoumeguAre T, Boudjeltia KZ, Hauzeur C, Schulman C, Vanhaeverbeek M, Wespes E,. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? BJU Int 2009; 104: 511-17
8. Wong P, Lawrentschuk N, Bolton DM,. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds. Curr Opin Urol 2009; 19: 7-12
9. Kang KK, Kim JM, Yu JY, Ahn BO, Yoo M, Kim YC,. Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia. Int J Urol 2007; 14: 946-51 (Pubitemid 47429170)
10. Liu CM, Lo YC, Wu BN, et al,. cGMP-enhancing and alpha 1a/alpha 1d-adrenoceptor blockade-derived inhibition of Rho-kinase by KMUP-1 provides optimal prostate relaxation and epithelial cell anti-proliferation efficacy. Prostate 2007; 67: 1397-410
11. Rees RW, Foxwell NA, Ralph DJ, Kell PD, Moncada S, Cellek S,. Y-27632, a rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 2003; 170: 2517-22 (Pubitemid 37414047)
12. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G,. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071-7 (Pubitemid 46216352)
13. O'Connor LT Jr, Vaughan ED Jr, Felsen D,. In vivo cystometric evaluation of progressive bladder outlet obstruction in rats. J Urol 1997; 158: 631-5 (Pubitemid 27327737)
14. Moncada S, Palmer RMJ, Higgs EA,. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-42
15. Gillespie J, Markerink M, Vente J,. cGMP-generating cells in the bladder wall: identification of distinct networks of interstitial cells. Br J Urol 2004; 94: 1114-24 (Pubitemid 39577105)
16. Heidler S, Temml C, Broessner C, et al,. Is the metabolic syndrome an independent risk factor for ED? J Urol 2007; 177: 651-4 (Pubitemid 46054028)
17. Bechara AJ,. Correlaciõn entre los síntomas del Tracto Urinario Inferior por Hiperplasia Benigna de Prostata (HPB) y la Disfunciõn Eréctil (DE). Available from:http://www.ttmed.com/ urology/latam/Articles.aspx?ID-VD=focuyVlWYDE%3d. Accessed on 22 March 2010
18. Azadzoi KM, Tarcan T, Siroky MB, Krane RJ,. Atherosclerosis-induced chronic ischemia causes bladder fibrosis and non-compliance in the rabbit. J Urol 1999; 161: 1626-35 (Pubitemid 29420853)
19. Azadzoi KM, Babayan RK, Kozlowski R, Siroky MB,. Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol 2003; 170: 659-63 (Pubitemid 36870279)
20. WHO. The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances. Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Policy and Standards. WHO Document Production Services. Geneva, Switzerland: WHO, 2006
21. Begg C, Cho M, Eastwood S, et al,. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. J Am Med Assoc 1996; 276: 637-9 (Pubitemid 26278070)
22. Jadad AR, Moore RA, Carroll D, et al,. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12 (Pubitemid 26120810)
23. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) [Computer Program]. Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003
24. Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY,. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res 2009; 21: 122-8
25. Mulhall JP, Guhring P, Parker M, Hopps C,. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3: 662-7
26. Ying J, Yao D, Jiang Y, Ren X, Xu M,. The positive effect of sildenafil on LUTS from BPH while treating ED. Zhonghua Nan Ke Xue 2004; 10: 681-3
27. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC,. Sildenafil influences lower urinary tract symptoms. BJU Int 2002; 90: 836-9 (Pubitemid 36693615)
28. Liquori G, Trombetta C, De Giorgi G, et al,. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med 2009; 6: 544-52
29. Bechara A, Romano S, Casabé A, et al,. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008; 5: 2170-8
30. Kaplan SA, Gonzales RR, Te AE,. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007; 51: 1717-23 (Pubitemid 46634750)
31. Porst H, McVary KT, Montorsi F, et al,. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009; 56: 727-35
32. McVary KT, Siegel RL, Carlsson M,. Sildenafil citrate improves erectile function and lower urinary tract symptoms independent of baseline body mass index or LUTS severity. Urology 2008; 72: 575-9
33. Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L,. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 2010; 105: 502-7
34. Guven EO, Balbay MD, Mete K, Serefoglu EC,. Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia. Int Urol Nephrol 2009; 41: 287-92
35. Güler C, Tüzel E, DoÄantekin E, Kiziltepe G,. Does sildenafil affect uroflowmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement? Urol Int 2008; 80: 181-5 (Pubitemid 351440514)
36. McVary KT, Roehrborn CG, Kaminetsky JC, et al,. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401-7 (Pubitemid 46435965)
37. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E,. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008; 53: 1236-44
38. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L,. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228-34
39. Higgins JPT, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60 (Pubitemid 37088507)